Sensorion’s sudden sensorineural hearing loss asset fails Phase II test
The asset failed to meet the primary goal of 15 decibels, a substantial improvement in pure tone audiometry in the…

The asset failed to meet the primary goal of 15 decibels, a substantial improvement in pure tone audiometry in the…
Day-90 data from a Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss treatment FX-322 in subjects…
ByBiotech firm Sensorion has received approval from the Independent Ethics Committee of Strasbourg in France to add new military sites…
Canadian biopharmaceutical firm Bellus Health has commenced patient enrolment in the Phase II RELIEF clinical trial of BLU-5937 to treat…